Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours

12 Mar 2020

Abstract excerpt

Abstract Immune checkpoint blockade (ICB)-based or natural cancer immune responses largely eliminate tumours. Yet, they require additional mechanisms to arrest those cancer cells that are not rejected. Cytokine-induced senescence (CIS) can stably arrest cancer cells, suggesting that interferon-dependent induction of senescence-inducing cell cycle regulators is needed to control those cancer cells that escape from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32165639
DOI: 10.1038/s41467-020-14987-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumoursPMID 32165639Read ↗

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.Semantic proximity Read ↗

Tumor Suppressor and Aging Biomarker p16INK4a Induces Cellular Senescence without the Associated Inflammatory Secretory PhenotypeSemantic proximity Read ↗

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i> / <i>NRAS</i> StatusSemantic proximity Read ↗

A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy.Semantic proximity Read ↗

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor GrowthSemantic proximity Read ↗

Cellular senescence in naevi and immortalisation in melanoma: a role for p16?Semantic proximity Read ↗

Senescence and Aging: Does It Impact Cancer Immunotherapies?Semantic proximity Read ↗

From cancer immunosurveillance to cancer immunotherapySemantic proximity Read ↗

The specific role of pRb in p16<sup>INK4A</sup>-mediated arrest of normal and malignant human breast cellsSemantic proximity Read ↗

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanomaSemantic proximity Read ↗

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanomaSemantic proximity Read ↗

p16INK4a-induced senescence is disabled by melanoma-associated mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.